Product nameAnti-Chk2 antibody
See all Chk2 primary antibodies
DescriptionRabbit polyclonal to Chk2
SpecificityDetects endogenous levels of total Chk2 protein.
Tested applicationsSuitable for: ICC/IF, ELISA, IHC-P, WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic non-phosphopeptide derived from Human Chk2 around the phosphorylation site of threonine 68.
- Human breast carcinoma tissue. Jurkat cell extracts.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
Purification notesAffinity purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen.
Our Abpromise guarantee covers the use of ab47433 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||1/200. Please see abreview for further details.|
|IHC-P||Use at an assay dependent concentration.|
|WB||1/500 - 1/1000. Detects a band of approximately 61 kDa (predicted molecular weight: 61 kDa).|
FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53.
Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily.
Contains 1 FHA domain.
Contains 1 protein kinase domain.
modificationsPhosphorylated by PLK4.
Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
- Information by UniProt
- CDS 1 antibody
- Cds1 antibody
- Cds1 homolog antibody
All lanes : Anti-Chk2 antibody (ab47433) at 1 µg
Lane 1 : extracts from Jurkat cells
Lane 2 : extracts from Jurkat cells incubated with immunizing peptide
Predicted band size: 61 kDa
Observed band size: 61 kDa
ab47433 (1/200) detecting Chk2 in HeLa cells in conjunction with a goat anti-mouse secondary antibody conjugated to Cy3 (red). Cells were counterstained with DAPI in order to highlight the nucleus (blue), treated with Bleomycin and incubated with an antibody against Histone H2AX in order to create and expose DNA double strand breaks (green). Please refer to abreviews for further details.
ab47433 at 1/100 dilution staining Chk2 in human breast carcinoma tissue section by Immunohistochemistry (Formalin/ PFA fixed paraffin embedded tissue sections). Right image show staining with ab47433 after incubation with specific peptide and left image show staining with untreated antibody.
This product has been referenced in:
- Zhao X et al. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Cell Death Dis 9:61 (2018). WB ; Human . Read more (PubMed: 29352124) »
- Luo Y et al. ß-catenin nuclear translocation induced by HIF-1a overexpression leads to the radioresistance of prostate cancer. Int J Oncol 52:1827-1840 (2018). Read more (PubMed: 29658569) »